spirapril
Trade name: renormax
Approved
Dec 29, 1994
Spirapril (Renormax) is an ACE inhibitor antihypertensive drug used to treat hypertension. Spiraprilat, the active metabolite of spirapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Spiraprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin. — NCATS
Clinical trial activity
2 trials · 6 clinical orgs · 2 marketing orgs
Earliest trial started Mar 1, 2000 (NCT00295542)
Timeline
1990s
- Dec 29, 1994
Earliest FDA Approval
Indications
Approved for
Mechanism of action
- Angiotensin-converting enzymeINHIBITOR
ACE inhibitor
Approval history
- approvedDec 29, 1994
Chemistry & pharmacology
SMILES
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2- Mol. weight
- 466.63 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL431 ↗
- WikipediaSpirapril ↗
- NCATSQS56V5Y7EC ↗
- ChEMBLCHEMBL579 ↗
- ChEMBLCHEMBL1200831 ↗
Also known as
- 1,4-dithia-7-azaspiro(4.4)nonane-8-carboxylic acid, 7-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (8s-(7(r*(r*)),8r*))-
- quadropril
- renormax
- renormax
- renormax
- renormax
- renormax
- renormax
- renpress
- sch 33844
- sch-33844
- sch-33844
- sch-33844
- spirapril
- spirapril
- spirapril
- spirapril
- spirapril
- spirapril
- spirapril
- spirapril
- spirapril
- spirapril
- spirapril
- spirapril hcl
- spirapril hcl
- spirapril hcl
- spirapril hydrochloride
- spirapril hydrochloride
- spirapril hydrochloride
- spirapril hydrochloride
- spirapril hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02817360 | Phase 4 | Feb 1, 2016 | Medical University of Vienna, University of Vienna |
| NCT00295542 | Phase 4 | Mar 1, 2000 | Government of Spain, University of Santiago, University of Vigo, Xunta de Galicia |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of Spain | Government | 1 | 0 | 1 | 2000 |
| Medical University of Vienna | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Santiago | Academic/Hospital | 1 | 0 | 1 | 2000 |
| University of Vienna | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Vigo | Academic/Hospital | 1 | 1 | 1 | 2000 |
| Xunta de Galicia | Academic/Hospital | 1 | 0 | 1 | 2000 |